On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Infobird Co., Ltd (NASDAQ: IFBD), A Company of Firsts

  • Infobird, a leading software-as-a-service (SaaS) provider of AI powered customer engagement solutions in China, is one of the few companies in China that has built a customer engagement SaaS on a cloud-native architecture, and has remained consistent with innovation and offering unique customer engagement solutions
  • The company’s products and services ride on the backbone of their self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform, and other powerful technologies.
  • Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools, allowing enterprises with a large customer base to cost-effectively personalize and automate their services
Infobird (NASDAQ: IFBD) has consistently innovated and offered unique customer-engagement solutions. The company has made a name for itself by leveraging proprietary next-generation technology, a product of years of research and development (“R&D”). This has allowed it to stamp its position as a leader in the Software-as-a-Service (“SaaS”) industry, particularly in the Chinese market. Infobird has been known to help companies manage the complete customer journey, starting from pre-sales activities to post-sale customer support. All this has ridden on the backbone of a self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform and many other such technologies (https://ibn.fm/uF6Th). Incremental improvements and developments over the years have rendered Infobird a pioneer in the industry and a trailblazer in what its technology can do from a customer relationship management (“CRM”) standpoint. Infobird is one of the very few companies in China to have built, from scratch, a customer engagement SaaS on a cloud-native architecture. A resource-intensive project in its development translates to cost-savings for clients who can scale their operations affordably and effectively without sacrificing on security or stability. This, in addition to Infobird’s no-code development, place it in a league of its own while also offering it an opportunity to further develop new SaaS with pre-programmed microservices at a significantly low cost and with quick reactions to new market opportunities. It is projected that the CRM market will be valued at $96.39 billion by 2027, up from $41.93 billion in 2019. Infobird plans to capitalize on this growth and play a central role in the industry’s growth. Recent client acquisitions such as SaSa, a Hong Kong beauty retailer, Zu Li Jian, a leading footwear brand in China, and a top fintech enterprise in China are all strong indications of a company positioning itself for the growth to come. Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools. It is achieving this through the integration of RPA analysis and Artificial Intelligence (“AI”), thereby allowing enterprises with a large customer base to personalize and automate their services while reducing their operational costs and improving efficiency. Infobird’s customer-engagement solutions are unlike any other in the market today. The company is constantly pushing the envelope with innovation and technology, further reinforcing its title as a company of firsts and also as the undisputed industry leader. For more information, visit the company’s website at www.Infobird.com/en/index. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

From Our Blog

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

April 24, 2024

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping […]

Rotate your device 90° to view site.